A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins

J Blake Marriott, Ian A Clarke, Anna Czajka, Keith Dredge, Kay Childs, Hon-Wah Man, Peter Schafer, Sowmya Govinda, George W Muller, David I Stirling, Angus G Dalgleish

    Research output: Contribution to journalArticle

    52 Citations (Scopus)

    Abstract

    Thalidomide is clinically useful in a number of cancers. Antitumor activity may be related to a number of known properties, including anti-tumor necrosis factor (TNF)-alpha and T-cell costimulatory and antiangiogenic activities. However, it may also involve direct antitumor effects. A series of second generation thalidomide analogues have been separated into two distinct groups of compounds, each with enhanced therapeutic potential, i.e., SelCIDs, which are phosphodiesterase (PDE) type IV inhibitors, and IMiDs, which have unknown mechanism(s) of action. We report here our efforts to determine direct antitumor effects of thalidomide and compounds from both groups. We found that one of the SelCID analogues (SelCID-3) was consistently effective at reducing tumor cell viability in a variety of solid tumor lines but had no effect on non-neoplastic cells. The antitumor activity was independent of known PDE4 inhibitory activity and did not involve cAMP elevation. Growth arrest was preceded by the early induction of G(2)-M cell cycle arrest, which led to caspase 3 mediated apoptosis. This was associated with increased expression of pro-apoptotic proteins and decreased expression of antiapoptotic bcl-2. Furthermore, extensive apoptosis in vivo was detected during SelCID-3-mediated inhibition of tumor growth in a murine xenotransplantation cancer model. Our results suggest that SelCID-3 represents a novel antitumor agent distinct from thalidomide and from previously characterized analogues with therapeutic potential against a range of solid tumors. This effect appears to be mediated via alterations in the expression of bcl-2 family proteins.
    Original languageEnglish
    Pages (from-to)593-599
    Number of pages7
    JournalCancer Research
    Volume63
    Issue number3
    Publication statusPublished - 1 Feb 2003

    Fingerprint

    Thalidomide
    Caspases
    Apoptosis
    Neoplasms
    Proteins
    Type 4 Cyclic Nucleotide Phosphodiesterase
    Heterologous Transplantation
    Apoptosis Regulatory Proteins
    Phosphodiesterase Inhibitors
    Growth
    Cell Cycle Checkpoints
    Caspase 3
    Antineoplastic Agents
    Cell Survival
    Tumor Necrosis Factor-alpha
    T-Lymphocytes
    Therapeutics
    SelCID-3

    Cite this

    Marriott, J. B., Clarke, I. A., Czajka, A., Dredge, K., Childs, K., Man, H-W., ... Dalgleish, A. G. (2003). A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Research, 63(3), 593-599.

    A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. / Marriott, J Blake; Clarke, Ian A; Czajka, Anna; Dredge, Keith; Childs, Kay; Man, Hon-Wah; Schafer, Peter; Govinda, Sowmya; Muller, George W; Stirling, David I; Dalgleish, Angus G.

    In: Cancer Research, Vol. 63, No. 3, 01.02.2003, p. 593-599.

    Research output: Contribution to journalArticle

    Marriott, JB, Clarke, IA, Czajka, A, Dredge, K, Childs, K, Man, H-W, Schafer, P, Govinda, S, Muller, GW, Stirling, DI & Dalgleish, AG 2003, 'A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins', Cancer Research, vol. 63, no. 3, pp. 593-599.
    Marriott, J Blake ; Clarke, Ian A ; Czajka, Anna ; Dredge, Keith ; Childs, Kay ; Man, Hon-Wah ; Schafer, Peter ; Govinda, Sowmya ; Muller, George W ; Stirling, David I ; Dalgleish, Angus G. / A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. In: Cancer Research. 2003 ; Vol. 63, No. 3. pp. 593-599.
    @article{bb59cde657004e10999019b633bc7e81,
    title = "A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins",
    abstract = "Thalidomide is clinically useful in a number of cancers. Antitumor activity may be related to a number of known properties, including anti-tumor necrosis factor (TNF)-alpha and T-cell costimulatory and antiangiogenic activities. However, it may also involve direct antitumor effects. A series of second generation thalidomide analogues have been separated into two distinct groups of compounds, each with enhanced therapeutic potential, i.e., SelCIDs, which are phosphodiesterase (PDE) type IV inhibitors, and IMiDs, which have unknown mechanism(s) of action. We report here our efforts to determine direct antitumor effects of thalidomide and compounds from both groups. We found that one of the SelCID analogues (SelCID-3) was consistently effective at reducing tumor cell viability in a variety of solid tumor lines but had no effect on non-neoplastic cells. The antitumor activity was independent of known PDE4 inhibitory activity and did not involve cAMP elevation. Growth arrest was preceded by the early induction of G(2)-M cell cycle arrest, which led to caspase 3 mediated apoptosis. This was associated with increased expression of pro-apoptotic proteins and decreased expression of antiapoptotic bcl-2. Furthermore, extensive apoptosis in vivo was detected during SelCID-3-mediated inhibition of tumor growth in a murine xenotransplantation cancer model. Our results suggest that SelCID-3 represents a novel antitumor agent distinct from thalidomide and from previously characterized analogues with therapeutic potential against a range of solid tumors. This effect appears to be mediated via alterations in the expression of bcl-2 family proteins.",
    author = "Marriott, {J Blake} and Clarke, {Ian A} and Anna Czajka and Keith Dredge and Kay Childs and Hon-Wah Man and Peter Schafer and Sowmya Govinda and Muller, {George W} and Stirling, {David I} and Dalgleish, {Angus G}",
    year = "2003",
    month = "2",
    day = "1",
    language = "English",
    volume = "63",
    pages = "593--599",
    journal = "Cancer Research",
    issn = "0008-5472",
    publisher = "AMER ASSOC CANCER RESEARCH",
    number = "3",

    }

    TY - JOUR

    T1 - A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins

    AU - Marriott, J Blake

    AU - Clarke, Ian A

    AU - Czajka, Anna

    AU - Dredge, Keith

    AU - Childs, Kay

    AU - Man, Hon-Wah

    AU - Schafer, Peter

    AU - Govinda, Sowmya

    AU - Muller, George W

    AU - Stirling, David I

    AU - Dalgleish, Angus G

    PY - 2003/2/1

    Y1 - 2003/2/1

    N2 - Thalidomide is clinically useful in a number of cancers. Antitumor activity may be related to a number of known properties, including anti-tumor necrosis factor (TNF)-alpha and T-cell costimulatory and antiangiogenic activities. However, it may also involve direct antitumor effects. A series of second generation thalidomide analogues have been separated into two distinct groups of compounds, each with enhanced therapeutic potential, i.e., SelCIDs, which are phosphodiesterase (PDE) type IV inhibitors, and IMiDs, which have unknown mechanism(s) of action. We report here our efforts to determine direct antitumor effects of thalidomide and compounds from both groups. We found that one of the SelCID analogues (SelCID-3) was consistently effective at reducing tumor cell viability in a variety of solid tumor lines but had no effect on non-neoplastic cells. The antitumor activity was independent of known PDE4 inhibitory activity and did not involve cAMP elevation. Growth arrest was preceded by the early induction of G(2)-M cell cycle arrest, which led to caspase 3 mediated apoptosis. This was associated with increased expression of pro-apoptotic proteins and decreased expression of antiapoptotic bcl-2. Furthermore, extensive apoptosis in vivo was detected during SelCID-3-mediated inhibition of tumor growth in a murine xenotransplantation cancer model. Our results suggest that SelCID-3 represents a novel antitumor agent distinct from thalidomide and from previously characterized analogues with therapeutic potential against a range of solid tumors. This effect appears to be mediated via alterations in the expression of bcl-2 family proteins.

    AB - Thalidomide is clinically useful in a number of cancers. Antitumor activity may be related to a number of known properties, including anti-tumor necrosis factor (TNF)-alpha and T-cell costimulatory and antiangiogenic activities. However, it may also involve direct antitumor effects. A series of second generation thalidomide analogues have been separated into two distinct groups of compounds, each with enhanced therapeutic potential, i.e., SelCIDs, which are phosphodiesterase (PDE) type IV inhibitors, and IMiDs, which have unknown mechanism(s) of action. We report here our efforts to determine direct antitumor effects of thalidomide and compounds from both groups. We found that one of the SelCID analogues (SelCID-3) was consistently effective at reducing tumor cell viability in a variety of solid tumor lines but had no effect on non-neoplastic cells. The antitumor activity was independent of known PDE4 inhibitory activity and did not involve cAMP elevation. Growth arrest was preceded by the early induction of G(2)-M cell cycle arrest, which led to caspase 3 mediated apoptosis. This was associated with increased expression of pro-apoptotic proteins and decreased expression of antiapoptotic bcl-2. Furthermore, extensive apoptosis in vivo was detected during SelCID-3-mediated inhibition of tumor growth in a murine xenotransplantation cancer model. Our results suggest that SelCID-3 represents a novel antitumor agent distinct from thalidomide and from previously characterized analogues with therapeutic potential against a range of solid tumors. This effect appears to be mediated via alterations in the expression of bcl-2 family proteins.

    M3 - Article

    C2 - 12566301

    VL - 63

    SP - 593

    EP - 599

    JO - Cancer Research

    JF - Cancer Research

    SN - 0008-5472

    IS - 3

    ER -